Press Release

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Alzheimer’s Drugs Market to Grow at a CAGR of 6.8% During the Period 2022-2027, Driven by Growing Ageing Population

According to a new report by EMR titled, ‘Global Alzheimer’s Drugs Market Report and Forecast 2022-2027’, the global Alzheimer’s Drugs market is expected to grow at a CAGR of 6.8% during the period 2022-2027, led by need for efficient management of the disease.

The global Alzheimer’s drugs market is expected to be driven by ageing global population and need for effective solutions to manage Alzheimer’s. It is reported that the number of cases of Alzheimer’s would nearly triple to 152.8 million by 2050. The prevalence of dementia across the world is reported to be as high as almost twenty-four million, and is projected to double every twenty years by 2040. As the global population continues to age, the number of individuals at risk are also expected to increase, especially among the very old. Significant regions include UAE, Qatar, USA, China, Germany, France, UK and Switzerland.

Alzheimer’s leads to problems with memory, thinking and behaviour. The disease worsens with time. While symptoms may widely vary, the symptoms that people first experience include forgetfulness severe enough to affect the ability to properly function at home or at work. Because of the disease, the sufferer may get confused, lost in familiar places, misplace things or experience trouble with language.

 

Key Developments

In 2021, it was reported that artificial intelligence revealed that current drugs could help combat Alzheimer’s Disease. A team at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) developed an artificial intelligence–based method to screen presently available medicines as probable treatments for Alzheimer’s Disease. The method could offer a quick and cost-effective way to repurpose existing therapies into new treatments for this progressive, debilitating neurodegenerative condition. Such developments are expected to drive the global Alzheimer’s drugs market. It could also help unveil novel, unexplored targets for therapy by indicating mechanisms of drug action.

In 2021, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s. Aduhelm was approved using the accelerated approval pathway, which could be used for a drug for a range of life-threatening illness that offers a meaningful therapeutic advantage over existing treatments.

In 2021, The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's investigational antibody therapy for Alzheimer's Disease (AD). The Breakthrough Therapy designation sought to expedite the development and review of drugs intended to treat a serious condition when preliminary clinical evidence indicated that the drug could exbibit considerable improvement on a clinically significant endpoint(s) over existing therapies with full FDA approval.

In 2021, Genentech’s Anti-Amyloid Beta Antibody Gantenerumab was granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease. Gantenerumab was an investigational antibody in Phase III development for early Alzheimer's disease (AD). Gantenerumab was the first and only anti-amyloid antibody being examined for subcutaneous administration in late-stage trials for the treatment of Alzheimer’s Disease.

Key Findings of the Report:

  • The global Alzheimer’s drugs market is expected to be driven by growing ageing population. 
  • The need to effectively manage the condition is expected to stimulate market growth.
  • North America, Middle East, Europe and Asia are likely to be key markets.

Market Analysis by Drug Class, Distribution Channel and Region:

  • By drug class, the market is segmented into Memantine, Cholinergic, Combined Drug, and Others.
  • By distribution channel, the market is classified into Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, and Others.
  • By region, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website:
www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*We at Expert Market Research always strive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER